Tali YaronEldar - Rosetta Genomics External Independent Director
Director
Ms. Tali YaronEldar is External Independent Director of the company since February 2007. Since January 2013 Ms. YaronEldar has served as founder of her own private practice. Between March 2007 and December 2012 Ms. YaronEldar had been a partner with the law firm of Tadmor Co. From January 2004 to March 2007 she was a partner at the law firm of Cohen YaronEldar Co. From January 2004 to January 2008 Ms. YaronEldar served as the Chief Executive Officer of Arazim Investment Company She has also served in a variety of public positions including as the Chief Legal Advisor of the Customs and V.A.T department of the Finance Ministry of the State of Israel from 1998 to 2001 and as the Commissioner of Income Tax and Real Property Tax Authority of the State of Israel from 2002 to 2004 since 2007.
Age | 50 |
Tenure | 17 years |
Professional Marks | MBA |
Phone | 972 73 222 0700 |
Web | http://www.rosettagx.com |
Rosetta Genomics Management Efficiency
The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (137.95) %, meaning that it created substantial loss on money invested by shareholders. Rosetta Genomics' management efficiency ratios could be used to measure how well Rosetta Genomics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rosetta Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Rosetta Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rosetta Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rosetta to invest in growth at high rates of return. When we think about Rosetta Genomics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Kenichi Nagai | NH Foods | N/A | |
Hilda OchoaBrillembourg | Cementos Pacasmayo SAA | 74 | |
David Toole | Lifevantage | 60 | |
Juan Vazquez | Cementos Pacasmayo SAA | N/A | |
William Lacey | Parker Hannifin | 55 | |
Gianfranco Zuniga | Cementos Pacasmayo SAA | N/A | |
Mark Petrarca | Topbuild Corp | 57 | |
Masashi Kataoka | NH Foods | N/A | |
Shuji Ohkoso | NH Foods | N/A | |
Hitoshi Yao | NH Foods | N/A | |
Thomas Williams | Chart Industries | 59 | |
Jason Adelman | Trio Tech International | 50 | |
Joe Davis | Natural Alternatives Internatio | 83 | |
Carl Camden | Topbuild Corp | 64 | |
Kenya Maruyama | NH Foods | N/A | |
Yasuko Kono | NH Foods | 61 | |
Kohei Akiyama | NH Foods | N/A | |
Alan Dunn | Natural Alternatives Internatio | 62 | |
Marco Garcia | Cementos Pacasmayo SAA | 60 | |
Richard Horowitz | Trio Tech International | 78 | |
Fumio Maeda | NH Foods | 58 |
Management Performance
Return On Equity | -137.95 | |||
Return On Asset | -60.19 |
Rosetta Genomics Leadership Team
Elected by the shareholders, the Rosetta Genomics' board of directors comprises two types of representatives: Rosetta Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rosetta. The board's role is to monitor Rosetta Genomics' management team and ensure that shareholders' interests are well served. Rosetta Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rosetta Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Sidransky, Independent Director | ||
Kenneth Berlin, CEO and Pres | ||
Anne Fields, IR Contact Officer | ||
Joshua Rosensweig, Director | ||
Dganit Bar, Chief Scientific Officer | ||
Brian Markison, Chairman, Observer To Board of Directors and Member of Nominating and Corporate Governance Committee | ||
Douglas Sites, Executive Vice President - Sales and Marketing | ||
Tal YaronEldar, Independent Director | ||
Eti Meiri, Vice President - Research | ||
Robert Wassman, Chief Medical Officer | ||
Oded Biran, General Counsel | ||
Roy Davis, Director | ||
Yitzhak Peterburg, Director | ||
Kevin Watson, Director, Reimbursement-Managed Care | ||
Ron Kalfus, CFO | ||
Gerald Dogon, External Independent Director | ||
Tali YaronEldar, External Independent Director |
Rosetta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rosetta Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -137.95 | |||
Return On Asset | -60.19 | |||
Operating Margin | (370.55) % | |||
Current Valuation | 2.09 M | |||
Shares Outstanding | 5.93 M | |||
Shares Owned By Insiders | 0.20 % | |||
Shares Owned By Institutions | 14.42 % | |||
Number Of Shares Shorted | 310.26 K | |||
Price To Earning | (0.09) X | |||
Price To Book | 1.01 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
CEOs Directory Screen CEOs from public companies around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |